Background: Hyaluronic acid based skinboosters present a low rheological profile that allows for even distribution throughout the dermis and focuses on improving skin's overall quality. Scientific efforts are ongoing with the aim of developing optimal skinboosters that meet specific clinical requirements and satisfactory overall results. Objective: Assess clinically the efficacy and safety of a newly developed skinbooster known as BtHLINE for face, neck and décolleté rejuvenation. Materials and Methods: In this prospective and single‐centre clinical trial, 81 volunteers with signs of cutaneous aging received three intradermal injections of BtHLINE every 3 weeks and were followed up for 15 days, 3 months and 6 months. Efficacy evaluation included the Multifactorial Aesthetic Scale (MAS), the Global Aesthetic Improvement Scale (GAIS) and the Likert's patient satisfaction questionnaire. Biometric parameters were also assessed over the facial area using specific aesthetic instrumentation such as Visioscan, Cutometer, Moisturemap and Visioface tools. Adverse events related to the treatment were registered throughout the study. Results: MAS score reached a statistically significant improvement at each time point for every treated area. Accordingly, GAIS and patient satisfaction surveys showed a clinically noticeable percentage of responders at the end of the follow‐up. The biometric analysis revealed that BtHLINE promoted a rapid and significant improvement that was maintained during the follow‐up period in terms of cutaneous uniformity, viscoelasticity, flexibility, firmness, water content, hydration, wrinkle depth, surface irregularities, scaling and smoothness. Adverse events were slight and considered as usual among skinboosters and were resolved within a few days. Conclusion: This study demonstrates that BtHLINE is safe and effective for the promotion of skin rejuvenation.

Dry eye disease (DED) is a multifactorial ocular surface disorder that significantly affects vision and quality of life. While artificial tears are the standard first-line therapy, their effectiveness is limited by the complex pathophysiology of DED. This study evaluated DayDrop^® Triple Action, a novel formulation combining hyaluronic acid (HA), ectoine, and carboxymethylcellulose (CMC), designed to enhance tear film stability and ocular surface protection. Physicochemical and rheological properties were assessed, including viscosity, pseudoplasticity, and viscoelastic behaviour under dynamic conditions, along with ectoine release over 24 h. An in vitro allergic conjunctivitis model using conjunctival fibroblasts exposed to a pro-allergic cytokine cocktail was employed to examine immunomodulatory effects. DayDrop^® Triple Action demonstrated high viscosity with pronounced pseudoplasticity and stable viscoelasticity, supporting improved mucoadhesion. The formulation provided sustained ectoine release and exhibited a positive immunomodulatory effect, likely linked to ectoine’s preferential hydration mechanism, which stabilizes membranes and reduces inflammatory signalling. These findings suggest that DayDrop^® Triple Action integrates viscoelastic optimization, osmoprotection, and targeted anti-inflammatory action, offering a promising non-pharmacological strategy for managing DED and allergic ocular surface disorders.

Background: Atopic dermatitis (AD) is a chronic inflammatory skin disorder. Revodiol Calming Cream^® (RCC) is a novel dermocosmetic product containing cannabidiol (CBD) and Annona cherimola fruit extract, designed for the management of atopic-prone and sensitive skin. Objective: Clinically assess the efficacy and safety of RCC in the management of atopic-prone and/or sensitive skin. Materials and methods: A prospective study included 20 adults and 22 children with mild-to-moderate atopic-prone skin. RCC was applied daily, for 56 days. Clinical evaluation included the SCORAD index, pruritus and dryness scales; and a Visual Analog Scale (VAS). Biometric assessments (Mexameter^®, Tewameter^®, Visioscan^®, Corneofix^®) were performed. Subjective satisfaction and quality of life (DLQI) were also recorded. Results: RCC was well tolerated, with no significant adverse events. After 56 days, SCORAD scores decreased by 55% in adults and 60% in children. Pruritus and dryness were significantly reduced, and VAS scores indicated a 65% decrease in discomfort. Biometric assessments demonstrated improvements in erythema, skin barrier function, topography, and desquamation. Subjective satisfaction reached 75% in both populations, and DLQI improved by 23%. Conclusions: The synergistic combination of CBD, Annona cherimola extract, and natural humectants offers a safe and effective daily dermocosmetic care for both adults and children.

Background: Hyaluronic acid is commonly used as a dermal filler for aesthetic purposes. Crosslinking allows a better performance once injected into the skin. A new filler, known as BtHCROSS, has been developed using a novel crosslinking technology (SARE technology). Objectives: To clinically assess the efficacy and safety of BtHCROSS for facial volumization. Methods: Two hundred and three volunteers with signs of facial aging received a single injection of BtHCROSS. Follow-up visits were established at 21 days, 6 months, and 9 months. Efficacy assessment included the Mid-Face Volume Loss Scale (MFVLS), Wrinkle Severity Rating Scale (WSRS), and Lip Fullness Grading Scale (LFGS). Global Aesthetic Improvement Scale (GAIS) and Likert’s patient satisfaction questionnaires were also registered. Biometric parameters were assessed using Visioscan, Cutometer, Moisturemap, and Visioface tools. Adverse events related to the study treatment were registered throughout the duration of the study. Results: Mid-Face Volume Loss Scale and WSRS scores showed a statistically significant improvement at both 6 and 9 months. Early noticeable results were also observed after 21 days in LFGS and WSRS scales. The specialist MD reported a GAIS improvement in more than 88%, 92%, and 76% of the volunteers at 21 days, 6, and 9 months, respectively, and the satisfaction percentage was above 70% in all cases. Biometric analysis showed a rapid and statistically significant improvement, maintained during the follow-up period. Conclusions: This study demonstrates that a single injection of BtHCROSS is safe and effective for the management of facial volumization for up to 9 months. Level of Evidence: 2 (Therapeutic): For image description, please refer to the figure legend and surrounding text.